Innate Pharma S.A. (IPHA)Healthcare | Biotechnology | Marseille, France | NasdaqGS
2.22 USD
-0.01
(-0.448%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.22 |
Hot Take ↕ | Aug. 22, 2026, 5:30 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish due to a recent earnings miss and weak statistical forecasts, despite a sharp intraday price recovery that suggests speculative interest. However, the long-term picture is severely compromised by a 64% cumulative decline over five years and four consecutive years of negative or flat growth, indicating a failing business model rather than a temporary setback. With negative free cash flow, negative operating margins, and no dividend history, there is no safety margin for a buy-and-hold strategy; the stock remains a high-risk speculative vehicle dependent entirely on future pipeline success. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065096 |
| AutoETS | 0.065096 |
| MSTL | 0.065117 |
| AutoARIMA | 0.065433 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 32.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.101 |
| Market Cap | 247,974,768 |
| Forward P/E | -3.52 |
| Beta | 0.86 |
| Website | https://www.innate-pharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.06730771 |
| Address1 | 117, Avenue de Luminy |
| Address2 | BP 30191 |
| All Time High | 11.95 |
| All Time Low | 1.17 |
| Ask | 2.21 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 51,250 |
| Average Daily Volume3 Month | 149,752 |
| Average Volume | 149,752 |
| Average Volume10Days | 51,250 |
| Beta | 0.861 |
| Bid | 2.19 |
| Bid Size | 1 |
| Book Value | -0.2710456 |
| City | Marseille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.22 |
| Current Ratio | 1.275 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.2895 |
| Day Low | 2.22 |
| Display Name | Innate Pharma |
| Earnings Call Timestamp End | 1,778,671,800 |
| Earnings Call Timestamp Start | 1,778,671,800 |
| Earnings Timestamp | 1,789,648,200 |
| Earnings Timestamp End | 1,789,648,200 |
| Earnings Timestamp Start | 1,789,648,200 |
| Ebitda | -53,309,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.686 |
| Enterprise To Revenue | 21.819 |
| Enterprise Value | 196,476,896 |
| Eps Current Year | -0.08867 |
| Eps Forward | -0.631 |
| Eps Trailing Twelve Months | -0.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 33 4 30 30 30 00 |
| Fifty Day Average | 1.9229 |
| Fifty Day Average Change | 0.29710007 |
| Fifty Day Average Change Percent | 0.15450625 |
| Fifty Two Week Change Percent | 6.730771 |
| Fifty Two Week High | 2.71 |
| Fifty Two Week High Change | -0.49 |
| Fifty Two Week High Change Percent | -0.18081181 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 1.0500001 |
| Fifty Two Week Low Change Percent | 0.89743596 |
| Fifty Two Week Range | 1.17 - 2.71 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,571,319,000,000 |
| Float Shares | 70,567,628 |
| Forward Eps | -0.631 |
| Forward P E | -3.5182252 |
| Free Cashflow | -34,073,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 164 |
| Fullday Change | -0.00999999 |
| Fullday Change Percent | -0.44843 |
| Fullday Price | 2.22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -34,615,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01401 |
| Held Percent Institutions | 0.0038400001 |
| Implied Shares Outstanding | 111,700,347 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. |
| Long Name | Innate Pharma S.A. |
| Market | us_market |
| Market Cap | 247,974,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_426137 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -49,177,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 244,478,146 |
| Number Of Analyst Opinions | 4 |
| Open | 2.26 |
| Operating Cashflow | -52,755,000 |
| Operating Margins | -6.89554 |
| Payout Ratio | 0.0 |
| Phone | 33 4 30 30 30 30 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.22 |
| Post Market Time | 1,787,947,804 |
| Previous Close | 2.23 |
| Price Eps Current Year | -25.036654 |
| Price Hint | 4 |
| Price To Book | -8.190504 |
| Price To Sales Trailing12 Months | 27.537453 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.144 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.44843006 |
| Regular Market Day High | 2.2895 |
| Regular Market Day Low | 2.22 |
| Regular Market Day Range | 2.22 - 2.2895 |
| Regular Market Open | 2.26 |
| Regular Market Previous Close | 2.23 |
| Regular Market Price | 2.22 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 11,427 |
| Return On Assets | -0.38849 |
| Revenue Growth | -0.467 |
| Revenue Per Share | 0.101 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 111,700,347 |
| Shares Percent Shares Out | 0.0023999999 |
| Shares Short | 227,041 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 163,552 |
| Short Name | Innate Pharma S.A. |
| Short Percent Of Float | 0.0023999999 |
| Short Ratio | 0.67 |
| Source Interval | 15 |
| Symbol | IPHA |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.5 |
| Total Cash | 34,310,000 |
| Total Cash Per Share | 0.366 |
| Total Debt | 22,573,000 |
| Total Revenue | 9,005,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.740595 |
| Two Hundred Day Average Change | 0.47940505 |
| Two Hundred Day Average Change Percent | 0.27542597 |
| Type Disp | Equity |
| Volume | 11,427 |
| Website | https://www.innate-pharma.com |
| Zip | 13,009 |